港股市场涨跌不一，拨康视云首日表现不佳 - 老虎社区

资讯资讯
帖子帖子
精选精选

- A扎西德勒A扎西德勒
  ·07-05
  瞎咧咧
  异动解读 | 拨康视云-B首日挂牌大跌7.43%，IPO超额认购热情难挽股价下跌
  临床阶段眼科生物科技公司拨康视云-B今日在港交所挂牌上市，盘中大跌7.43%，引发市场关注。拨康视云-B此前以每股10.1港元的价格完成全球发售，共发行6058.2万股股份，募集资金净额约5.22亿港元。公司香港公开发售部分获得78.78倍超额认购，显示出投资者的热烈兴趣。然而，这种热情似乎并未延续到二级市场。尽管IPO认购火热，但拨康视云-B上市首日表现不佳可能与多重因素有关。
  异动解读 | 拨康视云-B首日挂牌大跌7.43%，IPO超额认购热情难挽股价下跌
  662 评论
  1
  分享
  举报
- A扎西德勒A扎西德勒
  ·07-05
  瞎咧咧
  异动解读 | 拨康视云-B首日挂牌大跌7.43%，IPO超额认购热情难挽股价下跌
  临床阶段眼科生物科技公司拨康视云-B今日在港交所挂牌上市，盘中大跌7.43%，引发市场关注。拨康视云-B此前以每股10.1港元的价格完成全球发售，共发行6058.2万股股份，募集资金净额约5.22亿港元。公司香港公开发售部分获得78.78倍超额认购，显示出投资者的热烈兴趣。然而，这种热情似乎并未延续到二级市场。尽管IPO认购火热，但拨康视云-B上市首日表现不佳可能与多重因素有关。
  异动解读 | 拨康视云-B首日挂牌大跌7.43%，IPO超额认购热情难挽股价下跌
  662 评论
  1
  分享
  举报

{"themeInfo":{"themeId":"417db6c0ab0fdec18dfd33a47098c1b2","name":"港股市场涨跌不一，拨康视云首日表现不佳","description":"7月3日，港股市场开盘涨跌不一，恒生指数上涨0.05%，国企指数上涨0.03%，恒生科技指数上涨0.15%，红筹指数上涨0.37%。拨康视云首日跌近6%，腾讯控股也下跌0.3%。","image":"https://static.tigerbbs.com/5d7aa28ae12d14bd460750efb8ff3f3f","type":2,"style":4,"follow":false,"createTime":1751506543456,"userCounts":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/special/finance&rndata={\"themeId\":417db6c0ab0fdec18dfd33a47098c1b2}&rnconfig={\"headerBarHidden\": true}","subscribe":false,"allowFollow":false,"hasReward":false,"rewardScore":0,"rewardValidDate":0,"rewardEnd":false,"symbols":["HSI","TCEHY","HSTECH","00700"],"tweetCounts":1,"categoryId":"2929bb7468f5415f853fd96fb35d7c3b","options":[],"votedOptionId":"","totalUserCount":0,"followStatus":false,"themeName":"港股市场涨跌不一，拨康视云首日表现不佳","tweetAmount":1,"imageIsDefault":false},"tab":"essen","isFinancial":true,"allList":[{"id":453415630581936,"gmtCreate":1751719525697,"gmtModify":1751719527602,"author":{"id":"4208466508145652","authorId":"4208466508145652","name":"A扎西德勒","avatar":"https://static.tigerbbs.com/e61703b96313c20dec4d4c11d141970e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4208466508145652","authorIdStr":"4208466508145652"},"themes":[],"htmlText":"瞎咧咧","listText":"瞎咧咧","text":"瞎咧咧","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/453415630581936","repostId":"1191258223","repostType":2,"repost":{"id":"1191258223","kind":"news","weMediaInfo":{"introduction":"个股异动一手消息解读","home_visible":1,"media_name":"异动解读","id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"pubTimestamp":1751506361,"share":"https://www.laohu8.com/m/news/1191258223?lang=&edition=full","pubTime":"2025-07-03 09:32","market":"us","language":"zh","title":"异动解读 | 拨康视云-B首日挂牌大跌7.43%，IPO超额认购热情难挽股价下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1191258223","media":"异动解读","summary":"临床阶段眼科生物科技公司拨康视云-B今日在港交所挂牌上市，盘中大跌7.43%，引发市场关注。拨康视云-B此前以每股10.1港元的价格完成全球发售，共发行6058.2万股股份，募集资金净额约5.22亿港元。公司香港公开发售部分获得78.78倍超额认购，显示出投资者的热烈兴趣。然而，这种热情似乎并未延续到二级市场。尽管IPO认购火热，但拨康视云-B上市首日表现不佳可能与多重因素有关。","content":"<p>临床阶段眼科生物科技公司拨康视云-B（02592）今日在港交所挂牌上市，盘中大跌7.43%，引发市场关注。</p>\n\n<p>拨康视云-B此前以每股10.1港元的价格完成全球发售，共发行6058.2万股股份，募集资金净额约5.22亿港元。公司香港公开发售部分获得78.78倍超额认购，显示出投资者的热烈兴趣。然而，这种热情似乎并未延续到二级市场。</p>\n\n<p>尽管IPO认购火热，但拨康视云-B上市首日表现不佳可能与多重因素有关。作为一家临床阶段的生物科技公司，投资者可能对其短期盈利能力持谨慎态度。此外，近期市场对新股的态度趋于保守，加上整体市场情绪低迷，也可能影响了该股的表现。投资者需密切关注公司后续的临床试验进展和商业化进程，以评估其长期发展潜力。</p>","source":"ai_movement_cn","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | 拨康视云-B首日挂牌大跌7.43%，IPO超额认购热情难挽股价下跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | 拨康视云-B首日挂牌大跌7.43%，IPO超额认购热情难挽股价下跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">异动解读 </p>\n<p class=\"h-time\">2025-07-03 09:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>临床阶段眼科生物科技公司拨康视云-B（02592）今日在港交所挂牌上市，盘中大跌7.43%，引发市场关注。</p>\n\n<p>拨康视云-B此前以每股10.1港元的价格完成全球发售，共发行6058.2万股股份，募集资金净额约5.22亿港元。公司香港公开发售部分获得78.78倍超额认购，显示出投资者的热烈兴趣。然而，这种热情似乎并未延续到二级市场。</p>\n\n<p>尽管IPO认购火热，但拨康视云-B上市首日表现不佳可能与多重因素有关。作为一家临床阶段的生物科技公司，投资者可能对其短期盈利能力持谨慎态度。此外，近期市场对新股的态度趋于保守，加上整体市场情绪低迷，也可能影响了该股的表现。投资者需密切关注公司后续的临床试验进展和商业化进程，以评估其长期发展潜力。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02592":"拨康视云-B"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191258223","content_text":"临床阶段眼科生物科技公司拨康视云-B（02592）今日在港交所挂牌上市，盘中大跌7.43%，引发市场关注。\n拨康视云-B此前以每股10.1港元的价格完成全球发售，共发行6058.2万股股份，募集资金净额约5.22亿港元。公司香港公开发售部分获得78.78倍超额认购，显示出投资者的热烈兴趣。然而，这种热情似乎并未延续到二级市场。\n尽管IPO认购火热，但拨康视云-B上市首日表现不佳可能与多重因素有关。作为一家临床阶段的生物科技公司，投资者可能对其短期盈利能力持谨慎态度。此外，近期市场对新股的态度趋于保守，加上整体市场情绪低迷，也可能影响了该股的表现。投资者需密切关注公司后续的临床试验进展和商业化进程，以评估其长期发展潜力。","news_type":1,"symbols_score_info":{"02592":1}},"isVote":1,"tweetType":1,"viewCount":662,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"essenList":[{"id":453415630581936,"gmtCreate":1751719525697,"gmtModify":1751719527602,"author":{"id":"4208466508145652","authorId":"4208466508145652","name":"A扎西德勒","avatar":"https://static.tigerbbs.com/e61703b96313c20dec4d4c11d141970e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4208466508145652","authorIdStr":"4208466508145652"},"themes":[],"htmlText":"瞎咧咧","listText":"瞎咧咧","text":"瞎咧咧","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/453415630581936","repostId":"1191258223","repostType":2,"repost":{"id":"1191258223","kind":"news","weMediaInfo":{"introduction":"个股异动一手消息解读","home_visible":1,"media_name":"异动解读","id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"pubTimestamp":1751506361,"share":"https://www.laohu8.com/m/news/1191258223?lang=&edition=full","pubTime":"2025-07-03 09:32","market":"us","language":"zh","title":"异动解读 | 拨康视云-B首日挂牌大跌7.43%，IPO超额认购热情难挽股价下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1191258223","media":"异动解读","summary":"临床阶段眼科生物科技公司拨康视云-B今日在港交所挂牌上市，盘中大跌7.43%，引发市场关注。拨康视云-B此前以每股10.1港元的价格完成全球发售，共发行6058.2万股股份，募集资金净额约5.22亿港元。公司香港公开发售部分获得78.78倍超额认购，显示出投资者的热烈兴趣。然而，这种热情似乎并未延续到二级市场。尽管IPO认购火热，但拨康视云-B上市首日表现不佳可能与多重因素有关。","content":"<p>临床阶段眼科生物科技公司拨康视云-B（02592）今日在港交所挂牌上市，盘中大跌7.43%，引发市场关注。</p>\n\n<p>拨康视云-B此前以每股10.1港元的价格完成全球发售，共发行6058.2万股股份，募集资金净额约5.22亿港元。公司香港公开发售部分获得78.78倍超额认购，显示出投资者的热烈兴趣。然而，这种热情似乎并未延续到二级市场。</p>\n\n<p>尽管IPO认购火热，但拨康视云-B上市首日表现不佳可能与多重因素有关。作为一家临床阶段的生物科技公司，投资者可能对其短期盈利能力持谨慎态度。此外，近期市场对新股的态度趋于保守，加上整体市场情绪低迷，也可能影响了该股的表现。投资者需密切关注公司后续的临床试验进展和商业化进程，以评估其长期发展潜力。</p>","source":"ai_movement_cn","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | 拨康视云-B首日挂牌大跌7.43%，IPO超额认购热情难挽股价下跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | 拨康视云-B首日挂牌大跌7.43%，IPO超额认购热情难挽股价下跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">异动解读 </p>\n<p class=\"h-time\">2025-07-03 09:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>临床阶段眼科生物科技公司拨康视云-B（02592）今日在港交所挂牌上市，盘中大跌7.43%，引发市场关注。</p>\n\n<p>拨康视云-B此前以每股10.1港元的价格完成全球发售，共发行6058.2万股股份，募集资金净额约5.22亿港元。公司香港公开发售部分获得78.78倍超额认购，显示出投资者的热烈兴趣。然而，这种热情似乎并未延续到二级市场。</p>\n\n<p>尽管IPO认购火热，但拨康视云-B上市首日表现不佳可能与多重因素有关。作为一家临床阶段的生物科技公司，投资者可能对其短期盈利能力持谨慎态度。此外，近期市场对新股的态度趋于保守，加上整体市场情绪低迷，也可能影响了该股的表现。投资者需密切关注公司后续的临床试验进展和商业化进程，以评估其长期发展潜力。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02592":"拨康视云-B"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191258223","content_text":"临床阶段眼科生物科技公司拨康视云-B（02592）今日在港交所挂牌上市，盘中大跌7.43%，引发市场关注。\n拨康视云-B此前以每股10.1港元的价格完成全球发售，共发行6058.2万股股份，募集资金净额约5.22亿港元。公司香港公开发售部分获得78.78倍超额认购，显示出投资者的热烈兴趣。然而，这种热情似乎并未延续到二级市场。\n尽管IPO认购火热，但拨康视云-B上市首日表现不佳可能与多重因素有关。作为一家临床阶段的生物科技公司，投资者可能对其短期盈利能力持谨慎态度。此外，近期市场对新股的态度趋于保守，加上整体市场情绪低迷，也可能影响了该股的表现。投资者需密切关注公司后续的临床试验进展和商业化进程，以评估其长期发展潜力。","news_type":1,"symbols_score_info":{"02592":1}},"isVote":1,"tweetType":1,"viewCount":662,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"allBottom":false,"essenBottom":false}